Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression.

C-KIT encodes a tyrosine kinase receptor (KIT) that, when activated by its ligand (KL), stimulates proliferation, differentiation, migration, and survival. Greater than 70% of epithelial ovarian cancers coexpress c-KIT and KL. C-KIT and KL expression levels have been shown to be up-regulated by cAMP in some cell types. Additionally, cAMP is well-recognized for its anti-proliferative effects in cancer cells. The goal of these experiments was to investigate these seemingly contradictory consequences of cAMP treatment by: (1) confirming the growth inhibitory actions of cAMP on ovarian cancer cells; (2) investigating the ability of cAMP to affect c-KIT and KL expression in these cells; and (3) examining the possible role of endogenous and/or cAMP-regulated c-KIT and KL expression in ovarian cancer cell proliferation. HEY cells, an ovarian cancer cell line which expresses c-KIT and KL, were treated with dibutyryl cyclic AMP (dbcAMP), 8-bromo-cAMP, and cholera toxin over a range of concentrations. With all treatments, stimulation of cAMP signaling caused a dose-dependent inhibition of HEY cell proliferation by up to 40, 62, and 38%, respectively. This inhibition of proliferation correlated with a dose-dependent increase in c-KIT mRNA expression, yielding 4- to 7-fold elevations in transcript abundance; there were no changes in steady-state levels of KL transcripts. In order to determine whether KIT expression/activity was responsible for the observed decrease in proliferation, dbcAMP-treated HEY cells were exposed either to anti-KIT neutralizing antibodies or to the KIT inhibitor STI571. These experiments demonstrated that KIT inhibition did not alter the growth rate of cells or reverse the dbcAMP-induced inhibition of proliferation. These results suggest that cAMP signaling pathways regulate both cell proliferation and c-KIT expression in ovarian cancer cells; however, KIT is not assuming its well-established role as a growth factor.
AuthorsTanya J Shaw, Eniko J Keszthelyi, Angela M Tonary, Michaela Cada, Barbara C Vanderhyden
JournalExperimental cell research (Exp Cell Res) Vol. 273 Issue 1 Pg. 95-106 (Feb 01 2002) ISSN: 0014-4827 [Print] United States
PMID11795950 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2001 Elsevier Science.
Chemical References
  • Benzamides
  • Piperazines
  • Pyrimidines
  • RNA, Messenger
  • Stem Cell Factor
  • Imatinib Mesylate
  • Cyclic AMP
  • Proto-Oncogene Proteins c-kit
  • Animals
  • Apoptosis
  • Benzamides
  • Blotting, Northern
  • Blotting, Western
  • Cell Differentiation (drug effects)
  • Cell Division (drug effects)
  • Cell Membrane (physiology)
  • Cells, Cultured (drug effects, metabolism)
  • Cyclic AMP (pharmacology)
  • Female
  • Humans
  • Imatinib Mesylate
  • Ovarian Neoplasms (metabolism, pathology)
  • Phosphorylation
  • Piperazines
  • Precipitin Tests
  • Proto-Oncogene Proteins c-kit (genetics, metabolism)
  • Pyrimidines (pharmacology)
  • RNA, Messenger (metabolism)
  • Rats
  • Stem Cell Factor (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: